Blazena Kaderabkova's Discussions (32)

Discussions Replied To (28) Replies Latest Activity

"I agree with you that its time for " the compassionate use". What can we do for this?"

Blazena Kaderabkova replied Dec 4, 2011 to Ataluren update

18 Dec 14, 2011
Reply by Michelle Scaglione

"Hello Bernardo,   we are also wonder how it all happen. Did you read the PTC article…"

Blazena Kaderabkova replied Sep 9, 2011 to Stop Codon Mutation

26 Sep 10, 2011
Reply by Bernardo A. Iriberri

"No, see this link http://www.clinicaltrials.gov/ct2/show/NCT01247207?term=ataluren&a…"

Blazena Kaderabkova replied Aug 2, 2011 to Stop Codon Mutation

26 Sep 10, 2011
Reply by Bernardo A. Iriberri

"Dear Trinh, I know about Ataluren - PTC124 for stop codon mutation."

Blazena Kaderabkova replied Aug 1, 2011 to Stop Codon Mutation

26 Sep 10, 2011
Reply by Bernardo A. Iriberri

"Hello, my boy has also stop codon in exon 16"

Blazena Kaderabkova replied Jul 27, 2011 to Stop Codon Mutation

26 Sep 10, 2011
Reply by Bernardo A. Iriberri

" "

Blazena Kaderabkova replied Jul 9, 2011 to ATALUREN - confused about the information given from PTC Therapeutics and Genzyme

51 Jun 12, 2012
Reply by Tamara Walters

"http://www.santhera.com/index.php?docid=212&vid=&lang=en&am...  "

Blazena Kaderabkova replied May 9, 2011 to Idebenone

35 Jul 28, 2014
Reply by Rahul Deshpande

"Did you noticed, Santhera removed the estimated date of end study from December 2012…"

Blazena Kaderabkova replied May 9, 2011 to Idebenone

35 Jul 28, 2014
Reply by Rahul Deshpande

"Thank you, I just ordered Idebenone from Kirkman US. With shipment is the price very…"

Blazena Kaderabkova replied Apr 28, 2011 to Idebenone

35 Jul 28, 2014
Reply by Rahul Deshpande

"Thats great to hear it. How many miligrams daily does Joshua take?"

Blazena Kaderabkova replied Apr 28, 2011 to Idebenone

35 Jul 28, 2014
Reply by Rahul Deshpande

RSS

Need help using this community site? Visit Ning's Help Page.

Members

Events

© 2019   Created by PPMD.   Powered by

Badges  |  Report an Issue  |  Privacy Policy  |  Terms of Service